摘要:
This invention provides for inter alia, topical anthelmintic formulations which comprise a pharmaceutically active combination consisting of at least one macrocyclic compound and at least one compound selected from the group consisting of praziquantel, morantel and pyrantel, which are dissolved in a non-aqueous solvent or solvent mixture and optionally a thickening agent.
摘要:
This document relates to formulations for combating bacterial infections in animals which provide for improved long-acting oral and injectable formulations for systemic delivery of antibiotics, which are designed to achieve high bioavailability.
摘要:
This invention relates to a method and apparatus for forming soft capsules and provides novel processing flexibility. The apparatus comprises a three-way valve injector wedge. This injector wedge allows for set-up of the encapsulation machine with a placebo fill and quick change over to active fill. This conserves use of the active ingredient.
摘要:
Disclosed herein is an aqueous, injectable rapamycin solution comprising 0.1 to 10 percent of a concentrate solution of rapamycin in N,N-dimethylacetamide, at concentrations of rapamycin ranging from 0.25 mg/ml to 100 mg/ml, in combination with a diluent solution consisting of 0.1 to 10 weight percent of one or more polyoxyethylene sorbitan esters, 10 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent water, wherein the concentration of rapamycin in he combined solution ranges from 0.05 mg/ml to 5.0 mg/ml. Also disclosed is an aqueous, injectable solution of rapamycin, said solution comprising rapamycin in 0.1 to 10 weight percent N,N-dimethylacetamide, 0.09 to 7.5 weight percent of one or more polyoxyethylene sorbitan esters, 9 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent of water, wherein the concentration of rapamycin in the solution ranges from 0.05 mg/ml to 5.0 mg/ml. Preferred aqueous, injectable rapamycin solutions are those wherein one polyoxyethylene sorbitan ester is present and the polyethylene glycol present is polyethylene glycol 300.
摘要:
This invention relates to a method and apparatus for forming soft capsules and provides novel processing flexibility. The apparatus comprises a three-way valve injector wedge. This injector wedge allows for set-up of the encapsulation machine with a placebo fill and quick change over to active fill. This conserves use of the active ingredient.
摘要:
Disclosed herein is an aqueous, injectable rapamycin solution, obtained by a process consisting of mixing 5 to 30 volume percent of a concentrate solution of rapamycin in propylene glycol, at concentrations of rapamycin ranging from 0.5 mg/ml to 10 mg/ml, with a diluent solution consisting of 0.1 to 10 weight percent of one or more polyoxyethylene sorbitan esters, 10 to 60 weight percent of polyethylene glycol 200, 300 or 400 or a combination thereof and 30 to 89.9 volume percent water, wherein the concentration of rapamycin in the injectable solution ranges from 0.025 mg/ml to 3 mg/ml.
摘要:
Disclosed herein is an aqueous, injectable rapamycin solution comprising 40 to 75 volume percent of a concentrate solution of rapamycin in propylene glycol, at concentrations of rapamycin ranging from 0.25 mg/ml to 8 mg/ml, in combination with a diluent solution comprising water, wherein the diluent comprises 60 to 25 volume percent of the combined solution and the concentration of rapamycin in the combined solution ranges from 0.1 mg/ml to 4 mg/ml.
摘要:
The present invention comprises oral rapamycin formulations which contain, per 100 ml of the formulation, from about 0.01 to about 10.0 grams per 100 ml of rapamycin, from about 0.1 to about 10 ml of surfactant, from about 0.1 to about 25 ml of N,N-dimethylacetamide, and from about 65 to about 99.8 ml of a lecithin or phospholipid solution.
摘要:
The present invention provides novel oral rapamycin formulations which have, per 100 ml of the formulation, from about 0.01 grams to about 5.0 grams of rapamycin, from about 0.05% to about 10% by volume of surfactant, and from about 75% to about 99.95% by volume of a solution of phospholipid or lecithin in which the phospholipid or lecithin therein is 40% to 75% by weight.